All In Biotech

Drug Trial Radar · NCT06239467

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

PIKture-01: First-in-Human Study of the PI3KαH1047R Mutant-Selective Inhibitor OKI-219 as Monotherapy in Participants With Advanced Solid Tumors and as Part of Combination Therapy in Participants With Advanced Breast Cancer

Last checked: Nov 19, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Feb 26, 2024

Primary completion

Dec 31, 2026

Study completion Aug 1, 2027

Sponsor

Lead sponsor
OnKure, Inc.Industry
Sponsor type
Industry
First posted
Feb 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

OKI-219-101 is a Phase 1a/1b, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and efficacy of OKI-219 as monotherapy and in combination with other anti-cancer drugs. Phase 1a (Part A) will investigate escalating doses of OKI-219 monotherapy, and Phase 1b will investigate OKI-219 (at a tolerated dose determined in Part A) in combination with fulvestrant (Part B), trastuzumab and tucatinib (Part C), atirmociclib (Part D), and ribociclib and fulvestrant (Part E). Participants will continue to receive study treatment until disease progression, intolerable toxicity, or other study treatment withdrawal criteria are met.

Conditions

  • Advanced Cancer
  • Breast Cancer
  • Advanced Solid Tumors
  • PI3K Gene Mutation

Interventions

  • OKI-219Drug

    Oral twice daily

  • FulvestrantDrug

    Intramuscular injection

  • TrastuzumabDrug

    Intravenous (IV)

  • TucatinibDrug

    Oral twice daily

  • AtirmociclibDrug

    Oral twice daily

  • RibociclibDrug

    Oral once daily continuous for 21-days followed by 7 days off

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Identify maximum tolerated dose (MTD) of OKI-219 in monotherapyTime frame: Cycle 1 (First 28 days on treatment)
  2. Assess safety of OKI-219 as monotherapy or in combination with other anti-cancer therapies: incidence of SAEsTime frame: Through 30 days after last dose, an average of 1 year
  3. Assess safety of OKI-219 as monotherapy or in combination with other anti-cancer therapies: incidence of Grade 2 or greater treatment emergent adverse eventsTime frame: Through 30 days after last dose, an average of 1 year
  4. Assess rate of dose modifications during treatment with OKI-219 as monotherapy or in combination with other anti-cancer therapiesTime frame: Through last study dose, an average of 1 year

Locations

33 sites in 6 countries. Site status is shown where the registry gives one.

  • California Cancer Associates for Research and Excellence

    Encinitas, California

  • University of California San Diego UCSD

    La Jolla, California

  • UCLA Jonsson Comprehensive Cancer Center

    Los Angeles, California

  • Hoag - Huntington Beach

    Newport Beach, California

  • Regents of the University of Colorado

    Aurora, Colorado

  • Sarah Cannon Research Institute at HealthONE

    Denver, Colorado

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • Stony Brook University

    Stony Brook, New York

  • SCRI Oncology Partners - Nashville

    Nashville, Tennessee

  • NEXT Oncology Virginia

    Fairfax, Virginia

  • Fred Hutchinson Cancer Center

    Seattle, Washington

  • Institut Jules Bordet

    Anderlecht, Belgium

  • UZ Leuven - Campus Gasthuisberg

    Leuven, Belgium

  • GZA Hopsitals Campus Sint-Augustinus

    Wilrijk, Belgium

  • Centre de Lutte Contre le Cancer CLCC - Centre Georges Francois Leclerc (CGFL)

    Dijon, France

  • Centre Oscar Lambret

    Lille, France

  • Centre Leon Berard

    Lyon, France

  • Centre Antoine Lacassagne

    Nice, France

  • Hopital Lyon Sud

    Pierre-Bénite, France

  • Institut Gustave Roussy

    Villejuif, France

  • Ospedale San Raffaele

    Milan, Italy

  • Ospedale San Gerardo-ASST Monza

    Monza, Italy

  • Istituto Clinico Humanitas

    Rozzano, Italy

  • Gachon University Gil Medical Center

    Incheon, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • NEXT Oncology Phase I Unit / IOB- Hospital Quironsalud Barcelona

    Barcelona, Spain

  • Hospital Beata Maria Ana

    Madrid, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • START - Madrid

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.